Introduction
============

Extracorporeal membrane oxygenation (ECMO) is a temporary artificial extracorporeal support of the respiratory system and/or cardiac system used for the treatment of cardiopulmonary failure refractory to conventional therapies. More than 1,000 papers on ECMO published between January 2009 and May 2011 (PubMed search) clearly indicate a renewed interest in the technique, initially triggered by the CESAR trial publication \[[@B1]\] and the recent H1N1 flu pandemic. Indeed, during the pandemic the number of patients with acute respiratory distress syndrome (ARDS) who were not safely treatable with current clinical settings of mechanical ventilation (6 to 8 ml/kg tidal volume normalized on ideal body weight and plateau pressure lower than 30 to 35 cmH~2~O) and who therefore received extracorporeal respiratory support appeared to be greatly increased. After providing a brief background and some technical notes, we will review the most important and recent findings related to the technique, its application and future applications.

Long-term ECMO, as support for severe respiratory failure, was first successfully used in 1972 in an adult patient with post-traumatic respiratory failure \[[@B2]\]. A few years later, at the University of California, Bartlett and colleagues successfully treated a newborn with ECMO \[[@B3]\]. The enthusiasm for this new technique led to a randomized trial sponsored by the National Institutes of Health that compared venous-arterial ECMO with conventional mechanical respiratory support in severe ARDS \[[@B4]\]. After randomization of 90 patients the trial was stopped for futility because the mortality in both groups was around 90%. However, one should note that the greatest concern for mechanical ventilation, at that time, was the high fraction of inspired oxygen and not the high ventilator pressure/volume; that is, nonphysiological stress and strain. In this ECMO trial, therefore, the only difference in mechanical ventilation settings between treatment and control patients was a lower FiO~2~in the group that received the extracorporeal support. Moreover, the ECMO technology at these times was very primitive, with consistent risks for the patients due to high priming volumes of the extracorporeal circuits and elevated bleeding risks associated with systemic anti-coagulation. The limitations of this trial passed mostly unrecognized, however, and the discouraging results therefore led to the ECMO technique being abandoned worldwide.

During the same years, Kolobow was developing a new membrane lung optimized for carbon dioxide (CO~2~) removal as a possible application in patients with chronic obstructive pulmonary disease. While testing this new device in spontaneously breathing animals, however, we observed when part of the metabolically produced CO~2~was removed by the membrane lung that the ventilation of the animals proportionally decreased to maintain a constant blood partial pressure of CO~2~\[[@B5]\]. Artificial CO~2~removal could therefore be a powerful and valuable tool to control the respiratory drive up to complete apnea \[[@B6]\]. Indeed, the focus of extracorporeal support was shifted from oxygenation to CO~2~removal, aiming to provide lung rest to allow better healing. The hypothesis of limiting potential harmful stimuli was based uniquely on common sense, however, since concepts such as baby lung \[[@B7]\], atelectrauma \[[@B8]\], and so forth, were still unknown.

The first applications in humans of the concept of lung rest were reported in 1980 \[[@B9]\]. Soon after this experience a larger series of patients treated with extracorporeal CO~2~removal and low-frequency positive-pressure ventilation was described by the same authors \[[@B10]\]. However, a small randomized trial conducted in the United States at the beginning of the 1990s failed to show an outcome advantage of additional extracorporeal support as com-pared with conventional mechanical ventilatory support \[[@B11]\]. Despite this lack of evidence, a few centers around Europe continued to provide veno-venous extracorporeal support in selected series of patients, usually as a last resort \[[@B12]\]. In contrast, in the United States Bartlett and colleagues continued to provide extracorporeal support with standard mechanical ventilation, with more liberal indications and with encouraging results \[[@B13],[@B14]\].

A renewed interest in this technique arose after the publication of the CESAR trial, which clearly showed an improvement in the death rate and severe disability 6 months after randomization, when patients with severe respiratory failure were treated with extracorporeal support in an expert high-case-volume center compared with nonspecialized hospital care \[[@B1]\]. Moreover, although not the primary outcome, an actual difference in survival of around 25% was observed for patients considered for ECMO treatment at 28 days, the primary outcome of most ARDS literature. However, the final explosion of the application of this extracorporeal support was due to the use of ECMO as a rescue therapy in Australia and New Zealand during the H1N1 influenza pandemic \[[@B15]\]. This increased use is also probably due to several technical improvements, which allowed a simpler and safer use of the technique. Among these innovations we can mention the introduction of nonporous hollow fiber devices, characterized by low resistance to blood flow, and poly-methylpentene fibers that, combined with nonthrombogenic coatings, decrease the need for platelet transfusion and continuous heparin infusion. Moreover, recently introduced wire-reinforced walls of vascular access devices allow very thin cannula walls, reducing resistance to blood flow.

As the acronym ECMO includes several techniques with different aims, a brief reminder of the artificial lung\'s physiology is indicated to fully understand the different approaches, before discussing the latest reports on the topic.

Physiology of the artificial lung
=================================

Oxygenation
-----------

The amount of oxygen provided via artificial lung is a direct function of the blood flow. The blood flow required during veno-venous bypass to achieve acceptable arterial oxygenation is usually between 3 and 6 l/minute, partially depending on the cardiac output of the patient, on the hemoglobin concentration and on saturation. Of note, the gas flow required to fully oxygenate the incoming blood through the artificial lung may be quite low. For example, if we consider an entering hemoglobin saturation of 60% (with 3 l/minute extracorporeal blood flow, 10 g/dl hemoglobin concentration, 40 mmHg partial pressure of oxygen in venous blood and approximately 85 ml/l oxygen content), to reach 100% saturation we would need 200 ml/minute oxygen. Providing 0.2 l/minute pure oxygen to a highly efficient membrane lung would therefore theoretically be sufficient. This underlines the fact that what is of primary importance for artificial oxygenation is the extracorporeal blood flow passing through the membrane lung, and not its ventilation.

The effects of the oxygen supplied by the membrane lung on systemic oxygenation depend on the type of cannulation and on the possible changes induced by the artificial oxygenation on the function of the native lung. In a veno-venous circuit the artificial lung is in series with the natural lung. The improvement in arterial oxygenation, in this case, is due to the increased oxygen saturation of the blood flowing through shunt regions of the natural lung. Great improvements from oxygenation can therefore not be expected. Moreover, with this type of vascular access, as blood with high oxygen saturation reaches the pulmonary artery, the shunt fraction of the natural lung usually increases due to the loss of hypoxic vasoconstriction \[[@B16]\]. Despite this, the veno-venous approach with high flow, even with very high shunt in the natural lung, provides vital arterial oxygenation.

The veno-arterial approach, mostly used for cardiac support, implies the drainage of venous blood, its oxygenation and the subsequent input in the arterial tree through a cannulated artery. The improvement of systemic oxygenation with this technique is much better as compared with the veno-venous approach because the artificially oxygenated blood mixes with arterial blood and directly perfuses distal organs. Moreover, in this type of cannulation - the artificial lung being in parallel with the natural lung - there is no loss of hypoxic vaso-constriction, because no highly oxygenated blood enters the pulmonary artery. Despite the unique ability to also provide cardiac support, this type of cannulation is characterized by major disadvantages. First, an artery - typically the femoral artery - has to be cannulated with a large vascular catheter. This greatly increases the risk of ischemia of the inferior limb. Moreover, the aim of extracorporeal oxygenation (that is, to provide adequate oxygen supply to vital organs such as the brain and the heart) cannot be guaranteed through veno-arterial support if the input of oxygenated blood is performed distal to the great vessels; that is, through the femoral artery \[[@B16]\].

Carbon dioxide removal
----------------------

The removal of CO~2~is primarily a function of the flow of fresh gas. Theoretically it is possible to remove all of the metabolically produced CO~2~(rate of elimination of CO~2~about 200 to 250 ml/minute) from 0.5 to 1 l/minute venous blood due to its high CO~2~content (1 l of venous blood at partial pressure of CO~2~45 mmHg and pH 7.38, in standard conditions, contains about 500 ml CO~2~). In this regard, the local acidification of entering blood may further enhance CO~2~removal \[[@B17]\]. In the artificial lung, therefore, while high extracorporeal blood flow is required and low gas flow is sufficient for oxygenation, for CO~2~removal very low extracorporeal blood flow is sufficient and high gas flow is required.

The extracorporeal CO~2~removal allows the lungs to be put to rest, abolishing totally or partially the need for ventilation \[[@B18]\]. Indeed, if the main purpose of the application of the artificial lung is to allow lung rest and a gentle ventilation of the baby lung, low extracorporeal blood flows are sufficient \[[@B19]\]. In general, lower blood flow is feasible with smaller endovascular catheters and is associated with lower technical difficulties and complications. The approach of arterio-venous bypass with a pumpless device allows consistent CO~2~removal at the price of an arterio-venous fistula \[[@B20]-[@B22]\]. Low-flow CO~2~removal systems coupled to or uncoupled from hemo-filtration may remove 20 to 30% of the rate of metabolically produced CO~2~\[[@B23]-[@B26]\]. With artificial lungs actually available, total CO~2~clearance requires a blood flow in the order of 1 to 2 l/minute. Moreover, it is conceivable and desirable that, in the near future, regional anticoagulation (for example, with sodium citrate) will be available and will therefore greatly reduce the risk for bleeding due to systemic heparin infusion \[[@B27]\].

The H1N1 flu pandemic
=====================

The rebirth of extracorporeal respiratory support is primarily due to its use as a rescue therapy for life-threatening hypoxemia in Australia and New Zealand during the H1N1 flu pandemic \[[@B15]\]. The proper choice for such a purpose was therefore a veno-venous bypass with large-bore drainage catheters to allow high blood flows. The overall survival rate in this selected population was higher than 70%. After this report and in light of results from the CESAR trial \[[@B1]\], an impressive number of centers started to use this technique despite some scientists having expressed some doubt on the scientific evidence of its outcome advantages. The only evidence that led to the application of ECMO was the presence of moribund, severely hypoxemic patients that did not benefit from maximal mechanical ventilatory support \[[@B28]-[@B32]\]. Interestingly this technique was applied in Europe, the United States, South America, Canada and Asia, spreading as the H1N1 pandemic \[[@B33]-[@B38]\]. More than 1,000 papers were published from 2009 to May 2011; however, most articles were not related to the use of ECMO in H1N1 flu but referred for other indications, such as lung hyperinflation, cardiac failure or severe respiratory failure not caused by H1N1.

Extracorporeal support is a tool to buy time, maintaining life while awaiting improvement of the underlying disease. Therefore, it is theoretically crucial to take advantage of the extracorporeal support to minimize or, even better, to abolish the possible harm caused by an injurious mechanical ventilation. Extracorporeal CO~2~removal, in fact, partially or totally abolishes the need for ventilation, allowing one to apply a gentle ventilatory approach. It would therefore be interesting to know how mechanical ventilation was performed during extracorporeal support in the latest published studies. Surprisingly, however, the details on settings of mechanical ventilators are difficult to retrieve because when some mention of mechanical ventilation is made the information is limited to a general agreement with ARDS Net-work suggestions \[[@B39]\]. Some papers specified more details, which are still in line with lung-protective strategies aiming for a further reduction of tidal volume (for example, 3 to 5 ml/kg ideal body weight) while maintaining relative high mean airway pressure by high positive end-expiratory pressure (PEEP). In this scenario, however, we may find extreme differences \[[@B15],[@B36],[@B40]-[@B42]\]. As an example, in several centers in Italy it was not uncommon to observe very low tidal volumes with the respiratory rate limited to 7 or 8 breaths/minute and a high mean airway pressure related to high PEEP application. On the other hand, in other units - for example at the Karolinska Institute of Stockholm - the patients are kept awake with 5 cmH~2~O PEEP and ventilated with pressure support of 20 to 25 cmH~2~O (personal communication, Dr Palmér, Section Manager of the ECMO Center, Karolinska Institute, Stockholm, Sweden). In our ICU in Milan, patients were treated initially with high PEEP, above 15 cmH~2~O, and low-frequency ventilation \[[@B34]\]. To date, however, it is impossible to claim the superiority of a given treatment of the native lung during extracorporeal respiratory support as no studies are available on the topic. This lack of studies is primarily due to the scarcity of the patient population. However, it is important to emphasize - at least with regard to H1N1 patients - that the survival rate ranged from 56 to 79% throughout the centers, independent of the applied strategy of mechanical ventilation \[[@B15],[@B33],[@B34],[@B36]\].

We may therefore ask ourselves what we learned after this impressive utilization of extracorporeal support. First, extensive use of this technique all over the world in H1N1 patients confirmed that extracorporeal support is associated with high survival rates in severe hypoxemic patients. Moreover, we learned that these moribund patients may start time-buying extracorporeal respiratory support in the hospital of origin and thereafter be safely transferred to the referral ECMO centers. This practice has been clearly documented in Scandinavia \[[@B42],[@B43]\] as well as in Italy \[[@B44]\].

Indications
===========

Acute respiratory distress syndrome
-----------------------------------

After these considerations we may now discuss the actual indications for ECMO. The choice of the technique, which may vary from low-flow bypass with CO~2~removal to high-flow ECMO with total oxygenation support, depends on the patient\'s situation and the physician\'s preference.

### Extracorporeal assistance as a rescue therapy

If the aim is the treatment of life-threatening hypoxemia, the clear-cut indication is high-flow veno-venous ECMO. If the patient presents with severe cardiac failure, however, veno-arterial ECMO must be used. The obvious question is whether these types of treatment are associated with a better outcome.

The recently published CESAR trial provided some clues in this regard \[[@B1]\]. Many physicians, however, were not fully convinced by the investigators\' approach \[[@B45]-[@B47]\]. In fact, this pragmatic study really tested the differences in outcome between a specialized center with high-volume activity and single centers with low-volume activity. Despite these limitations the study strongly indicated that treatment with extracorporeal support may increase the survival rate in a selected population of patients with ARDS. We may ask ourselves why, after over 30 years, a classical, adequately powered randomized trial has not been conducted in these severely hypoxemic patients. To test a possible mortality difference of 10% between the ECMO and control arms would require enrollment of about 1,000 patients (with 90% power using a cutoff value for statistical significance of 0.05). Given that the enrollment rate of previous large randomized trials on severe ARDS \[[@B48]-[@B51]\] was approximately 0.3 patients/unit/month and that only one-third of these patients could have met the criteria for ECMO application - that is, severe refractory hypoxemia (partial pressure of oxygen \<100 mmHg despite 100% FiO~2~) \[[@B52]\] - 20 ECMO centers would take over 40 years to complete the study (the CESAR trial took about 8 years). It therefore seems to us that a classical randomized trial is not feasible.

Despite this, there seems a high likelihood that extracorporeal support has saved the lives of some extremely severe patients. ECMO seems to be indicated in this type of patient because the risks from complications of the technique seem irrelevant when almost certain death can be predicted. The question is different when severe hypoxemia is still manageable with more conventional approaches (high PEEP, high-frequency oscillatory ventilation, 100% FiO~2~, nitric oxide, and so forth). In these patients, the possible benefits of extracorporeal support have to be balanced with the only lethal complication of ECMO, which is intracranial hemorrhage. Unfortunately there are few data to predict with reasonable confidence the incidence of intracranial hemorrhage in adults \[[@B53]\]. According to the Italian ECMOnet experience, intracranial hemorrhage occurred in one patient out of 49 (personal communication, Dr Patroniti, San Gerardo Hospital, Monza, Italy). In our experience, however, the incidence was about 5% and this complication occurred both in subjects treated for hematologic malignancy and in patients with no predictable cause of increased bleeding susceptibility. Any time we consider a patient for ECMO we must therefore keep in mind this unpredictable and lethal complication.

### Extracorporeal assistance to provide lung rest

If the aim of applying the artificial lung is not to assure oxygenation during hypoxemic emergency but to assure complete lung rest or to allow a protective lung strategy, CO~2~removal is indicated. A technique that solely removes CO~2~is applied in arterio-venous bypass \[[@B22]\]. With this technique the extracorporeal blood flow is low and oxygen transfer negligible, the input blood in the oxygenator being arterial and therefore already highly saturated. In our opinion, however, in ARDS patients it is safe to remove CO~2~using devices that also allow the performance of blood flows up to 2 to 2.5 l/minute. In this way, if needed, not only may lung rest be provided but also oxygenation maintained, in case of natural lung function deterioration.

Extracorporeal assistance for indications other than ARDS
---------------------------------------------------------

Increased confidence in using extracorporeal assistance led to use of the technique in different clinical conditions. Although outside the aim of the present review, the following conditions should be noted.

### Bridge to lung transplant

Extracorporeal assistance has been successfully used as a bridge to lung transplant in patients with terminal chronic obstructive pulmonary disease or cystic fibrosis. Of note, there is an increased tendency to maintain those patients awake, and spontaneously breathing, without the need for intubation \[[@B54]\].

### Lung hyperinflation

Lung hyperinflation is common during chronic obstructive pulmonary disease exacerbation or during status asthmaticus. In this condition, when noninvasive mechanical ventilation fails, extracorporeal support may be applied. The primary aim is to remove CO~2~, therefore reducing spontaneous ventilation and allowing progressive lung deflation \[[@B55]\].

### Cardiac failure

There is much experience providing extracorporeal assistance during cardiogenic shock. In this condition the approach is obviously venous-arterial, providing not only respiratory but also cardiac assistance.

Conclusion
==========

Recent events moved the spots of scientific interest once again on extracorporeal techniques of respiratory support. Since the first experiences with ECMO, technology has hugely evolved, making extracorporeal respiratory support safer and more cost-effective. Indeed, extracorporeal respiratory support is now an attractive strategy for the treatment of any type of respiratory failure in addition to, or even as an alternative to, mechanical ventilation.
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